



HAL
open science

What specificity for the clinical aspects of investigational advanced therapy medicinal products?

Éloïse Gennet, Florence Sabatier, Julie Veran, Diack Adja Fatou, Nada Mongalgi, Véronique Andrieu, Michael Morrison, Aurélie Mahalatchimy

► To cite this version:

Éloïse Gennet, Florence Sabatier, Julie Veran, Diack Adja Fatou, Nada Mongalgi, et al.. What specificity for the clinical aspects of investigational advanced therapy medicinal products?. Annual Conference of the European Association of Health Law, Apr 2022, Ghent, Belgium. halshs-03780286

HAL Id: halshs-03780286

<https://shs.hal.science/halshs-03780286>

Submitted on 19 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

What specificity for the clinical aspects of investigational advanced therapy medicinal products?

Eloïse Gennet¹, Florence Sabatier², Julie Véran³, Diack Adja Fatou⁴, Nada Mongalgi⁴, Véronique Andrieu⁵, Michael Morrison⁶, Aurélie Mahalatchimy⁷

¹ Post-doctoral Researcher in Law, Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix-Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France; ² Professor of Hematology and Biotherapy, Pharmaceutical Sciences Faculty, C2VN INSERM INRAE 1263 AIX Marseille University, Director of the cell therapy research centre at Marseille Public Hospital (AP-HM), France; ³ Responsible of Cell therapy/Advanced Therapy Medicinal Products' production at Marseille Public Hospital (AP-HM), Biotherapies Clinical Investigation Center, France; ⁴ Students in 4th year of Pharmaceutical Sciences, Aix-Marseille University, France; ⁵ Senior lecturer in Industrial Pharmacy and Pharmaceutical Regulation, Faculty of Pharmacy, Aix-Marseille University, Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; ⁶ Senior Research Fellow in Social Sciences, Centre for Health Law and Emerging Technologies (HeLEX), University of Oxford, United Kingdom; ⁷ Permanent Researcher in law at the French National Centre for Scientific Research (CNRS, CR), Law Faculty, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.

Acknowledgements: This work has been supported by ANR-funded I-BioLex project (ANR-20-CE26-0007-01, coord. A. Mahalatchimy). M. Morrison is funded by the Leverhulme Trust through grant no RPG-2017-330.

BACKGROUND AND AIM

While Advanced Therapy Medicinal Products (ATMPs), an European legal classification of medicinal products based on genes, cells and tissues, raises specific quality issues, the latter are particularly acute in the context of clinical trials and thus cannot be treated as any other medicine, notably because of their manufacturing constraints and short shelf-life. In comparison to more traditional medicinal products, ATMPs have been subject to specific regulatory provisions in the European Union (EU) since 2007. In addition, many guidelines have also been adopted to consider the issues raised by ATMPs.

Clinical trials with ATMPs are generally governed by Regulation 536/2014 on clinical trials, which came into effect on 31 January 2022, as well as ICH E6 Guidelines on Good Clinical Practice (GCP). For clinical trials conducted in the EU, it is mandatory to comply with GCP. Most importantly for investigational ATMPs, the European Commission has adopted and published 2019 Guidelines on GCP specific to ATMPs, as required by Article 4 of Regulation (EC) n°1394/2007 on ATMPs. These guidelines are both adapting ICH guidelines to ATMPs characteristics and providing additional measures that have been considered necessary. However, they are not exhaustive as they explain only some specificities of ATMPs and they are complementary to the general rules. Not only are these guidelines targeting ATMPs specifically, they also have a dedicated section on the quality of investigational ATMPs.

The aim of this poster is to highlight the specificity of quality requirements of investigational ATMPs in order to reveal the specific challenges they are addressing and why these challenges deserve separate regulation in order to demonstrate quality in clinical trials.

METHODOLOGY

The research work has consisted in examining the elements of the 2019 Guidelines from the European Commission that were dedicated to the quality of investigational ATMPs, in order to analyze them through the lens of the corresponding scientific literature.


The first stage of the research has consisted in the study of aforementioned guideline through the analysis of the general structure of the guidelines regarding the challenges covered, and a more detailed analysis of the quality aspects, especially regarding the section on the quality of investigational ATMPs. More specifically, the subsections of the guideline that were relevant to the analysis of specific quality requirements for investigational ATMPs were identified. Then, the main issues at stake for each subsection were formulated and organised by topic.

During the second stage of the research, a literature review was conducted in PubMed and Web of Science, using queries such as ("Investigational Advanced Therapy Medicinal Products") or ("Advanced Therapy Medicinal Products" AND "Clinical Trials" [Title]). The research generated 29 results, among which only 4 articles were selected for further content analysis, on the basis of their relevance for the study of specific quality requirements for investigational ATMPs at the EU level of governance.

At the last stage of research, analysis of the literature was compared to the results from the guideline analysis.

RESULTS

Main challenges for ATMPs: the design and conduct of clinical trials



Conclusion

Case by case evaluation of the various aspects of the design of the early-phase ATMPs clinical trials and various levels of documentation to be provided for clinical trials authorisation

Guidelines' specific requirements concerning the quality of experimental ATMPs

General considerations

Compliance with the European Commission Guidelines on Good Manufacturing Practice for Advanced Therapy Medicinal Products

Starting materials

- Impact of the variability of donor or patient based starting material to define release specifications for cell-based ATMPs (for autologous product: disease status of the patient)
- Confirmation of compliance with European directives on quality and safety of human tissues and cells, and human blood and blood components for their donation, procurement and testing
- Confirmation of the traceability system's establishment with bidirectional tracking of tissues and cells from donation to administration

Storage, transport and handling conditions

- Detailed instructions of the reconstitution process from sponsor to the administration site:
 - o To specify if the reconstitution requires the use of solvents and/or other materials
 - o Reconstitution to be described in the Investigators Brochure or in its Annex
 - o For complex reconstitution process: training to be provided

Investigational ATMP Reconstitution before administration

- Detailed conditions from sponsor to investigator (e.g., temperature conditions)
 - o When short-shelf life: timelines to be clearly documented in trial records
 - o For handling processes: adequate training of the investigator

Medical devices (MD)

- MD integrated within the investigational ATMP (combined ATMP):
 - o Information on the characteristics, performance and intended use of MD, **AND**
 - o Compliance with the relevant MD general safety and performance requirements (Regulation 2017/745), **OR** justification of the MD suitability for the intended use on the basis of these requirements
- MD used with investigational ATMP (not integrated):
 - o Cover letter with:
 - List of MD to be investigated in the clinical trial
 - Statement on the existence of CE-marked for the MD intended use.
 - Summary information on characteristics, performance, intended use, and regulatory status of MD

DISCUSSION AND CONCLUSION

Many different aspects are covered in this guideline. They are **essential to patients' well-being and product safety**. They permit to **avoid mistakes and minimize risks through the design and the conduct of clinical trials**. As such, they guide medicines' developers in the innovative sector of ATMPs.

ATMPs are innovative and more complicated than traditional or other biological drugs → precise and specific requirements which can raise logistical issues, such as the adaptation needed in terms of equipment and logistics⁽²⁾.

High risks associated with the manufacturing process and the product → higher expectations for control

Many sources of variability can influence the quality of the investigational ATMPs → they should all be considered and minimized to avoid distorted results⁽⁵⁾

Variability can lead to the discontinuation of the clinical trial although it can also be related to a strategic decision of the sponsor, the poor recruitment of clinical trials' participants or serious adverse events⁽⁵⁾

For phase 1 clinical trials, quality and safety strongly overlap.

Solution to address the challenges of quality in the context of ATMPs clinical trials: to engage in a pre-clinical trials application meeting with regulatory agencies, such ANSM as it is proposed in France⁽⁴⁾

REFERENCES

- (1) European Commission, Guideline on Good Clinical Practice specific to Advanced Therapy Medicinal Products, 10 October 2019, C(2019) 7140 final.
- (2) Iglesias-Lopez C, Agustí A, Vallano A, Obach M, Methodological characteristics of clinical trials supporting the marketing authorisation of advanced therapies in the European Union. *Front Pharmacol.* 2021 Nov 29; 12:773712. doi: 10.3389/fphar.2021.773712.
- (3) Jones DR, McBlane JW, McNaughton G, Rajakumaraswamy N, Wydenbach K. A regulatory perspective of clinical trial applications for biological products with particular emphasis on Advanced Therapy Medicinal Products (ATMPs). *Br J Clin Pharmacol.* 2013 Aug;76(2):203-9. doi: 10.1111/bcp.12057. PMID: 23216470; PMCID: PMC3731595.
- (4) Lucas-Samuel S, Ferry N, Trouvin JH. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products. *Adv Exp Med Biol.* 2015;871:73-85. doi: 10.1007/978-3-319-18618-4_4. PMID: 26374213.
- (5) Hanna E, Rémuzat C, Auquier P, Toumi M. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. *J Mark Access Health Policy.* 2016 Aug 2;4. doi: 10.3402/jmahp.v4.32232. PMID: 27570614; PMCID: PMC4973442.
- (6) European Commission, Guidelines of 22 November 2017 on Good Manufacturing Practice for Advanced Therapy Medicinal Products, C(2017) 7694.
- (7) Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC; OJ L 33, 8.2.2003, p. 30-40, CELEX number: 32002L0098
- (8) Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, OJ L 102, 7.4.2004, p. 48-58, CELEX number: 32004L0023